These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
274 related items for PubMed ID: 9458208
1. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. Furst DE, Clements PJ, Steen VD, Medsger TA, Masi AT, D'Angelo WA, Lachenbruch PA, Grau RG, Seibold JR. J Rheumatol; 1998 Jan; 25(1):84-8. PubMed ID: 9458208 [Abstract] [Full Text] [Related]
2. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Kissin EY, Merkel PA, Lafyatis R. Arthritis Rheum; 2006 Nov; 54(11):3655-60. PubMed ID: 17075814 [Abstract] [Full Text] [Related]
3. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE. Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694 [Abstract] [Full Text] [Related]
4. Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis. Manneschi LI, Del Rosso A, Milia AF, Tani A, Nosi D, Pignone A, Generini S, Giacomelli R, Cerinic MM. Rheumatology (Oxford); 2005 May; 44(5):607-13. PubMed ID: 15728417 [Abstract] [Full Text] [Related]
7. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241 [Abstract] [Full Text] [Related]
8. Increased serum pentraxin 3 in patients with systemic sclerosis. Iwata Y, Yoshizaki A, Ogawa F, Komura K, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Takehara K, Sato S. J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457 [Abstract] [Full Text] [Related]
9. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR. Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112 [Abstract] [Full Text] [Related]
10. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T, Takehara K. Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059 [Abstract] [Full Text] [Related]
11. Lack of relationship between functional ability and skin score in patients with systemic sclerosis. Herrick A, Rooney B, Finn J, Silman A. J Rheumatol; 2001 Feb; 28(2):292-5. PubMed ID: 11246664 [Abstract] [Full Text] [Related]
12. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Yamaguchi Y, Ono J, Masuoka M, Ohta S, Izuhara K, Ikezawa Z, Aihara M, Takahashi K. Br J Dermatol; 2013 Apr; 168(4):717-25. PubMed ID: 23110679 [Abstract] [Full Text] [Related]
13. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Del Rosso A, Boldrini M, D'Agostino D, Placidi GP, Scarpato A, Pignone A, Generini S, Konttinen Y, Zoppi M, Vlak T, Placidi G, Matucci-Cerinic M. Arthritis Rheum; 2004 Jun 15; 51(3):475-81. PubMed ID: 15188336 [Abstract] [Full Text] [Related]
14. Durometry for the assessment of skin disease in systemic sclerosis. Kissin EY, Schiller AM, Gelbard RB, Anderson JJ, Falanga V, Simms RW, Korn JH, Merkel PA. Arthritis Rheum; 2006 Aug 15; 55(4):603-9. PubMed ID: 16874783 [Abstract] [Full Text] [Related]
15. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, Silman AJ, Allegar N, Varga J, Massa M. J Rheumatol; 1993 Nov 15; 20(11):1892-6. PubMed ID: 8308774 [Abstract] [Full Text] [Related]
16. Increased expression of basic fibroblast growth factor in skin of patients with systemic sclerosis. Lawrence A, Khanna D, Misra R, Aggarwal A. Dermatol Online J; 2006 Jan 27; 12(1):2. PubMed ID: 16638370 [Abstract] [Full Text] [Related]
17. Increased pigmentation in scleroderma. Pope JE, Shum DT, Gottschalk R, Stevens A, McManus R. J Rheumatol; 1996 Nov 27; 23(11):1912-6. PubMed ID: 8923365 [Abstract] [Full Text] [Related]
18. A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. Genovese MC, Chakravarty EF, Boyle DL, Tutuncu Z, Thorburn CM, Halilhodzic M, Kroll S, Baughman J, Stewart S, Kavanaugh A. J Rheumatol; 2005 Dec 27; 32(12):2345-50. PubMed ID: 16331761 [Abstract] [Full Text] [Related]
19. Elevated vascular endothelial growth factor in systemic sclerosis. Choi JJ, Min DJ, Cho ML, Min SY, Kim SJ, Lee SS, Park KS, Seo YI, Kim WU, Park SH, Cho CS. J Rheumatol; 2003 Jul 27; 30(7):1529-33. PubMed ID: 12858453 [Abstract] [Full Text] [Related]
20. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, Medsger TA. Arthritis Rheum; 2007 Aug 27; 56(8):2740-6. PubMed ID: 17665460 [Abstract] [Full Text] [Related] Page: [Next] [New Search]